Page 2 of 8, showing 50 records out of 368 total, starting on record 51, ending on 100
| Publication |
Category |
Year |
|
160. Labrie, F. (1991) Intracrinology. Mol. Cell. Endocrinol., 78: C113-C118. |
Prostate Cancer |
1991 |
|
149. Labrie, F. (1992) Stratégie efficace et peu coûteuse pour la détection du cancer de la prostate à un stade précoce alors que la guérison est possible. Médecine/Sciences, 8: 703-706. |
Prostate Cancer |
1992 |
|
134. Labrie, F. (1993) GNRH agonists in prostate cancer, in GnRH analogues - The State of the Art 1993, New York, Parthenon Publishing, pp 103-121. |
Prostate Cancer |
1993 |
|
135. Labrie, F. (1993) Intracrinology: its impact on prostate cancer. Curr. Opin. Urol., 3: 381-387. |
Prostate Cancer |
1993 |
|
136. Labrie, F. (1993) Mechanism of action and pure antiandrogenic properties of Flutamide. Cancer, 72: 3816-3827. |
Prostate Cancer |
1993 |
|
137. Labrie, F. (1993) Non-steroidal antiandrogens, in: Droz, J.P., Cvitkovic, E., Armand, J.P. et Khoury, S., eds: Handook of Chemotherapy in Clinical Oncology, London, Scientific Communication International Ltd., pp 389-391. |
Prostate Cancer |
1993 |
|
138. Labrie, F. (1993) Present status of endocrine therapy of prostate cancer. Eur. Urol. Today, 3: 10-11. |
Prostate Cancer |
1993 |
|
124. Labrie, F. (1994) Intracrinology and Cancer Therapy. Science Watch, 5: 3-4. |
Prostate Cancer |
1994 |
|
125. Labrie, F. (1994) Les antiandrogènes dans le cancer de la prostate. La Lettre du Pharmacologue, 8: 190-195. |
Prostate Cancer |
1994 |
|
126. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to 342: 901-5, 1993]. Lancet, 343: 491. |
Prostate Cancer |
1994 |
|
127. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to Cheney re 343: 491-2, 1994]. Lancet, 343: 976-977. |
Prostate Cancer |
1994 |
|
110. Labrie, F. (1995) Endocrine therapy of prostate cancer: optimal form and timing. J. Clin. Endocrinol. Metab., 80: 1066-1071. |
Prostate Cancer |
1995 |
|
81. Labrie, F. (1997) Flutamide plus castration in patients with previously untreated prostate cancer [Letter to the Editor re: Noldus et al. 47: 713-8, 1996]. Urology, 50: 479. |
Prostate Cancer |
1997 |
|
48. Labrie, F. (2000) Prostate cancer and combined androgen blockade at all stages of disease, in: Khayat, D. et Hortobagyi, G.N., eds: Progress in Anti-Cancer Chemotherapy, France, Springer, pp 171-187. |
Prostate Cancer |
2000 |
|
46. Labrie, F. (2000) Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. Prostate, 43: 214-222. |
Prostate Cancer |
2000 |
|
47. Labrie, F. (2000) Screening and hormonal therapy of localized prostate cancer show major benefits on survival. Cancer J. Sci. Am., 6: S182-S187. |
Prostate Cancer |
2000 |
|
38. Labrie, F. (2001) Le cancer de la prostate: blocage combiné des androgènes comme traitement à tous les stades de la maladie. Oncologie, 3: 3-12. |
Prostate Cancer |
2001 |
|
33. Labrie, F. (2002) Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol, 198: 77-87. |
Prostate Cancer |
2002 |
|
34. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. |
Prostate Cancer |
2002 |
|
30. Labrie, F. (2003) Hormonal therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate Cancer: Biology, Diagnosis and Management, London, UK, Oxford University Press, pp 301-314. |
Prostate Cancer |
2003 |
|
21. Labrie, F. (2004) Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility. Brazilian J Urol, 30: 3-12. |
Prostate Cancer |
2004 |
|
22. Labrie, F. (2004) Major role of androgen blockade in the success of prostate cancer treatment: cure has become a very good possibility. Prostate Cancer Communication Newsletter, 20: 3-11. |
Prostate Cancer |
2004 |
|
23. Labrie, F. (2004) Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl, 25: 305-313. |
Prostate Cancer |
2004 |
|
24. Labrie, F. (2004) Status of androgen blockade in prostate cancer in 2003, in: Koutsilieris, M. et Labrie, F., eds: Prostate cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 157-170. |
Prostate Cancer |
2004 |
|
16. Labrie, F. (2006) Keyrole of endocrinology in the victory against prostate cancer. Bull. Cancer, 93: 949-58. |
Prostate Cancer |
2006 |
|
7. Labrie, F. (2007) Multiple intracrine hormonal targets in the prostate: oportunities and challenges. BJU Int, 100: 48-51. |
Prostate Cancer |
2007 |
|
4694. Labrie, F. (2008) Comment to: Prostate specific antigen (PSA)-based screening. Int J Urol, 15: 757-762. |
Prostate Cancer |
2008 |
|
97. Labrie, F., Bélanger, A., Cusan, L., Labrie, C., Simard, J., Luu-The, V., Gomez, J.L., Diamond, P., Candas, B. (1996) History of LHRH agonist and combination therapy in prostate cancer. Endocrine-Related Cancer, 3: 243-278. |
Prostate Cancer |
1996 |
|
139. Labrie, F., Bélanger, A., Dupont, A., Luu-The, V., Simard, J., Labrie, C. (1993) Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med., 16: 475-492. |
Prostate Cancer |
1993 |
|
172. Labrie, F., Bélanger, A., Dupont, A., Pelletier, G., Luu-The, V., Simard, J., Cusan, L., Labrie, C., Lachance, Y., Poulin, R., Dupont, E., Zhao, H.F., Martel, C. (1990) Synthèse périphérique des androgènes chez l'homme. Génétique moléculaire du système et sa prise en compte dans le traitement du cancer de la prostate. Médecine/Sciences, 6: 261-267. |
Prostate Cancer |
1990 |
|
19. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J., Candas, B. (2005) Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews, 26: 361-379. |
Prostate Cancer |
2005 |
|
140. Labrie, F., Bélanger, A., Simard, J., Labrie, C., Dupont, A. (1993) Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first line therapy. Cancer, 71: 1059-1067. |
Prostate Cancer |
1993 |
|
111. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) Intracrinologie: autonomie et liberté des tissus périphériques. Ann. Endocrinol. (Paris), 56: 23-29. |
Prostate Cancer |
1995 |
|
98. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Cusan, L., Gomez, J., Diamond, P., Candas, B. (1996) Sources d'androgènes chez l'homme et traitement hormonal du cancer de la prostate (Chapter 16), in: Belaisch, J., Drodowsky, M.A. et Vermeulen, A., eds: Progrès en Andrologie: Endocrinologie Masculine, Doin, pp 215-229. |
Prostate Cancer |
1996 |
|
61. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. |
Prostate Cancer |
1999 |
|
62. Labrie, F., Candas, B. (1999) Bicalutamide versus Flutamide in combination therapy [Letter to the Editor re: Schellhammer et al. 50: 330-336, 1997]. Urology, 53: 662-663. |
Prostate Cancer |
1999 |
|
63. Labrie, F., Candas, B. (1999) The Quebec study shows a 69% decrease in prostate cancer death [Authors' Response to comment of Alexander and Prescott on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 137. |
Prostate Cancer |
1999 |
|
64. Labrie, F., Candas, B. (1999) Various statistical analyses indicate a marked reduction of prostate cancer death in the Quebec trial [Authors' Response to comment of Boer and Schroder on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 132-134. |
Prostate Cancer |
1999 |
|
49. Labrie, F., Candas, B. (2000) Androgen blockade in prostate cancer [Letter-to-the-Editor]. Lancet, 356: 341-342. |
Prostate Cancer |
2000 |
|
39. Labrie, F., Candas, B., Cusan, L., Gomez, J.L. (2001) The Laval University screening trial results (Chapter 17), in: Thompson, I.M., Resnick, M.I. et Klein, E.A., eds: Current Clinical Urology, Prostate Cancer Screening, Totowa, NJ, Humana Press Inc., pp 255-279. |
Prostate Cancer |
2001 |
|
25. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Bélanger, A., Brousseau, G., Lévesque, J. (2004) Screening decreases prostate cancer mortality: 11-year follow-up on the 1988 Quebec prospective randomized controlled trial. The Prostate, 59: 311-318. |
Prostate Cancer |
2004 |
|
82. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Lemay, M. (1997) Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen [Letter to the Editor: Reply to Brown and Feuer re 47: 212-7, 1996]. Urology, 49: 306-307. |
Prostate Cancer |
1997 |
|
100. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M. (1996) Diagnosis of advanced or non-curable prostate cancer can be practically eliminated by prostate-specific antigen. Urology, 47: 212-217. |
Prostate Cancer |
1996 |
|
26. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Lévesque, J., Chevrette, E., Brousseau, G. (2004) Prostate Cancer Screening and Early Treatment: The Only Possibility for a Major Impact on Survival in Prostate Cancer, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 67-78. |
Prostate Cancer |
2004 |
|
65. Labrie, F., Candas, B., Dupont, A., Cusan, L., Gomez, J.L., Suburu, R.E., Diamond, P., Lévesque, J., Bélanger, A. (1999) Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate, 38: 83-91. |
Prostate Cancer |
1999 |
|
35. Labrie, F., Candas, B., Gomez, L.J., Cusan, L. (2002) Can combined androgen blockade provide long term control or possible cure of localized prostate cancer? Urology, 60: 115-119. |
Prostate Cancer |
2002 |
|
112. Labrie, F., Crawford, D.; (1995) Anti-androgens in treatment of prostate cancer. Lancet, 346: 1030-1031. |
Prostate Cancer |
1995 |
|
66. Labrie, F., Cusan, J., Gomez, J., Levesque, J., Candas, B. (1999) Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. Society of the Study of the Aging Male, 2: 33-43. |
Prostate Cancer |
1999 |
|
101. Labrie, F., Cusan, L., Dupont, A., Gomez, J.-L., Simard, J., Luu-The, V., Pelletier, G., Labrie, C., Bélanger, A. (1996) Androgen receptor antagonists (Chapter 28), in: Adashi, E.Y., Rock, J.A. et Rosenwaks, Z., eds: Reproductive Endocrinology, Surgery and Technology, Philadelphia, Lippincott-Raven Publishers, pp 559-583. |
Prostate Cancer |
1996 |
|
27. Labrie, F., Cusan, L., Gomez, J., Luu-The, V., Candas, B., Bélanger, A., Labrie, C. (2004) Major impact of hormonal therapy in localized prostate cancer - death can already be an exception. JSBMB, 92: 327-344. |
Prostate Cancer |
2004 |